A prospective study on prediction of sensitivity to trastuzumab using gene expression of peripheral blood mononuclear cells

A prospective study on prediction of sensitivity to trastuzumab using gene expression of peripheral blood mononuclear cells - A prospective study on prediction of sensitivity to trastuzumab using gene expression of peripheral blood mononuclear cells

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000002660

Enrollment

Registered

2009-10-22

Start date

2009-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

bresat cancer

Interventions

single-agent trastuzumab

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. histologically confirmed HER2-positive breast cancer patients 2. Stage IV or recurrent breast cancer 3. hormone-receptor negative or hormone-refractory 4. non life-threatning disease 5. at least one measurable lesion 6. ejection fraction no less than 55% 7. written consent by the patient

Exclusion criteria

Exclusion criteria: 1. uncontrolled CNS metastasis 2. co-existence of heart failure or past history of decline in cardiac function during trastuzumab treatment 3. pregnant women

Design outcomes

Primary

Measure	Time frame
response rate after enrichment by gene signature	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026